Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 05, 2022

SELL
$32.6 - $53.05 $9,128 - $14,854
-280 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$41.79 - $135.3 $11,701 - $37,884
280 New
280 $17,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $154M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Smith Group Asset Management, LLC Portfolio

Follow Smith Group Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith Group Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Smith Group Asset Management, LLC with notifications on news.